leupeptins and Gaucher-Disease

leupeptins has been researched along with Gaucher-Disease* in 2 studies

Other Studies

2 other study(ies) available for leupeptins and Gaucher-Disease

ArticleYear
Chemical and biological approaches synergize to ameliorate protein-folding diseases.
    Cell, 2008, Sep-05, Volume: 134, Issue:5

    Loss-of-function diseases are often caused by a mutation in a protein traversing the secretory pathway that compromises the normal balance between protein folding, trafficking, and degradation. We demonstrate that the innate cellular protein homeostasis, or proteostasis, capacity can be enhanced to fold mutated enzymes that would otherwise misfold and be degraded, using small molecule proteostasis regulators. Two proteostasis regulators are reported that alter the composition of the proteostasis network in the endoplasmic reticulum through the unfolded protein response, increasing the mutant folded protein concentration that can engage the trafficking machinery, restoring function to two nonhomologous mutant enzymes associated with distinct lysosomal storage diseases. Coapplication of a pharmacologic chaperone and a proteostasis regulator exhibits synergy because of the former's ability to further increase the concentration of trafficking-competent mutant folded enzymes. It may be possible to ameliorate loss-of-function diseases by using proteostasis regulators alone or in combination with a pharmacologic chaperone.

    Topics: Cell Line; Fibroblasts; Gaucher Disease; Humans; Leupeptins; Lysosomal Storage Diseases; Molecular Chaperones; Pentacyclic Triterpenes; Protein Folding; Proteins; Tay-Sachs Disease; Triterpenes

2008
Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts.
    European journal of biochemistry, 1987, Apr-01, Volume: 164, Issue:1

    The biosynthesis and maturation of glucocerebrosidase were studied in fibroblasts from patients with the neurological and non-neurological forms of Gaucher disease and in control cells. In control fibroblasts the precursor of glucocerebrosidase (62-63 kDa), observed after a short pulse with [35S]methionine, was converted during the chase period to a 66-kDa intermediate form and, finally, to the 59-kDa mature protein. In fibroblasts from patients with the non-neurological phenotype of Gaucher disease (type 1) the same biosynthetic forms were seen as in control fibroblasts. These biosynthetic forms correspond to the three-banded pattern seen in control and Gaucher type 1 fibroblast extracts analysed by the immunoblotting procedure, or after electrophoresis and fluorography of extracts of such fibroblasts cultured for 5 days with [14C]leucine. The 59-kDa protein seen in type 1 fibroblasts was unstable and disappeared after a prolonged chase; this disappearance was not observed when the cells were grown in the presence of leupeptin. In fibroblasts from patients with the neurological forms of Gaucher disease (types 2 and 3) the 62.5-kDa precursor of glucocerebrosidase was present in near-normal amounts after a short pulse, but the 59-kDa form was not detected even when cells were cultured with leupeptin. These results are in accordance with the absence of the 59-kDa band in immunoblots of types 2 and 3 fibroblast extracts. Culturing of type 1, type 2 and type 3 Gaucher fibroblasts in the presence of leupeptin led to an increase in the activity of glucocerebrosidase.

    Topics: Cell Line; Cross Reactions; Fibroblasts; Gaucher Disease; Glucosidases; Glucosylceramidase; Humans; Immunosorbent Techniques; Leupeptins; Methionine; Molecular Weight; Mutation

1987